The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
New targets for treatment against HCV infection
Pan Q, van der Laan LJ. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):505-15. doi: 10.1016/j.bpg.2012.10.002.
Source
Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room L-462, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Electronic address: q.pan@erasmusmc.nl.
Abstract
Owing to the tremendous effort from both academia and industry, drug development for hepatitis C virus (HCV) infection has been flourishing, with a range of pipeline compounds at various stages of development. Although combination of the recently launched serine protease inhibitors will further improve the response rate of current interferon-based therapy, some intrinsic limitations of these compounds and the tendency of resistance development by the virus, urge the development of alternative or additional therapeutic strategies. In this article we provide an overview of different host and viral factors which have emerged as new potential targets for therapeutic intervention using state-of-the-art technologies.